Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Breast 2

Conditions

Colorectal Neoplasms 27Neoplasm Metastasis 5Advanced Solid Tumors 5Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors (Excluding Breast Cancer) 2Urologic Diseases 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Refractory Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1

Interventions

trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors (Excluding Breast Cancer) × trifluridine tipiracil drug combination × Clear all
NCT01867879 2024-09-05

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
44 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01874522 2024-09-05

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Taiho Oncology, Inc.

Phase 1 Completed
46 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡